CoChat

Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

Open access
Chaft, Jamie E., Oezkan, Filiz, Kris, Mark G., Bunn, Paul A., Wistuba, Ignacio I., Kwiatkowski, David J., Owen, Dwight H., Tang, Yan, Johnson, Bruce E., Lee, Jay M., Lozanski, Gerard, Pietrzak, Maciej, Seweryn, Michal, Byun, Woo Yul, Schulze, Katja, Nicholas, Alan, Johnson, Ann, Grindheim, Jessica, Hilz, Stephanie, Shames, David S., Rivard, Chris, Toloza, Eric, Haura, Eric B., McNamee, Ciaran J., Patterson, G. Alexander, Waqar, Saiama N., Rusch, Valerie W., Carbone, David P., LCMC study investigators, Waqar, Saiama N., Shum, Elaine, Nagasaka, Misako, Koczywas, Marianna, Garon, Edward B., Finley, David J., Camidge, David R., Carlisle, Jennifer W., Blasberg, Justin D. · 2022 · Nature Medicine
Cited by 247

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

In an ongoing, open-label, single-arm phase II study (NCT02927301), 181 patients with untreated, resectable, stage IB–IIIB non-small cell lung cancer received two doses of neoadjuvant atezolizumab monotherapy. The primary end point was major pathological response (MPR; ≤10% viable malignant cells) in resected tumors without EGFR or ALK alterations. Of the 143 patients in the primary end point analysis, the MPR was 20% (95% confidence interval, 14–28%). With a minimum duration of follow-up of 3 years, the 3-year survival rate of 80% was encouraging. The most common adverse events during the neoadjuvant phase were fatigue (39%, 71 of 181) and procedural pain (29%, 53 of 181), along with expected immune-related toxicities; there were no unexpected safety signals. In exploratory analyses, MPR was predicted using the pre-treatment peripheral blood immunophenotype based on 14 immune cell subsets. Immune cell subsets predictive of MPR in the peripheral blood were also identified in the tumor microenvironment and were associated with MPR. This study of neoadjuvant atezolizumab in a large cohort of patients with resectable non-small cell lung cancer was safe and met its primary end point of MPR ≥ 15%. Data from this single-arm, non-randomized trial suggest that profiles of innate immune cells in pre-treatment peripheral blood may predict pathological response after neoadjuvant atezolizumab, but additional studies are needed to determine whether these profiles can inform patient selection and new therapeutic approaches.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-022-01962-5

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 247

Metadata

Authors
Chaft, J. E., Oezkan, F., Kris, M. G., Bunn, P. A., Wistuba, I. I., Kwiatkowski, D. J., Owen, D. H., Tang, Y., Johnson, B. E., Lee, J. M., Lozanski, G., Pietrzak, M., Seweryn, M., Byun, W. Y., Schulze, K., Nicholas, A., Johnson, A., Grindheim, J., Hilz, S., Shames, D. S., Rivard, C., Toloza, E., Haura, E. B., McNamee, C. J., Patterson, G. A., Waqar, S. N., Rusch, V. W., Carbone, D. P., LCMC study investigators, Waqar, S. N., Shum, E., Nagasaka, M., Koczywas, M., Garon, E. B., Finley, D. J., Camidge, D. R., Carlisle, J. W., & Blasberg, J. D.
Venue
Nature Medicine
Published
2022-09-12
Volume
28
Issue
10
Pages
2155-2161
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4295442856
Cited by
247
References
15
FWCI
19.76
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. https://app.cochat.ai/papers/10.1038/s41591-022-01962-5
The paper
Chaft, J. E., Oezkan, F., Kris, M. G., Bunn, P. A., Wistuba, I. I., Kwiatkowski, D. J., Owen, D. H., Tang, Y., Johnson, B. E., Lee, J. M., Lozanski, G., Pietrzak, M., Seweryn, M., Byun, W. Y., Schulze, K., Nicholas, A., Johnson, A., Grindheim, J., Hilz, S., . . . Blasberg, J. D. (2022). Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. Nature Medicine. https://doi.org/10.1038/s41591-022-01962-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.